SCHEMBL2848900

SCHEMBL2848900

CC(Nc1nc2ccc(Oc3cncc(-n4cncn4)n3)cc2s1)C1CCCCC1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PI4KA P42356 2/20 0.41
PI4KB Q9UBF8 2/20 0.41
PIP5K1C O60331 1/20 0.41
PIK3CG P48736 1/20 0.41
CSF1R P07333 7/20 0.38
MAPT P10636 3/20 0.38
NPC1 O15118 2/20 0.38
RAB9A P51151 2/20 0.38
USP30 Q70CQ3 3/20 0.38
PKM P14618 1/20 0.36
HCRTR1 O43613 1/20 0.36
ITK Q08881 1/20 0.35
ALDH1A1 P00352 2/20 0.34
KDM4E B2RXH2 1/20 0.34
HPGD P15428 1/20 0.34
MAPK1 P28482 1/20 0.34
HSD17B10 Q99714 1/20 0.34
MAOA P21397 1/20 0.33
MAOB P27338 1/20 0.33
USP2 O75604 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2848892 1.00 PI4KA (0.41) PI4KAPI4KBPIP5K1CPIK3CGCSF1R
SCHEMBL2843313 0.89 PI4KA (0.41) PI4KAPI4KBPIP5K1CPIK3CGCSF1R
SCHEMBL2843310 0.89 PI4KA (0.41) PI4KAPI4KBPIP5K1CPIK3CGCSF1R
SCHEMBL2845141 0.85 CSF1R (0.41) PI4KAPI4KBPIP5K1CPIK3CGCSF1R
SCHEMBL2845143 0.85 CSF1R (0.41) PI4KAPI4KBPIP5K1CPIK3CGCSF1R
SCHEMBL2847775 0.81 CSF1R (0.51) CSF1RHCRTR1PDGFRBKIT
SCHEMBL2845186 0.78 CSF1R (0.49) PI4KAPI4KBPIP5K1CPIK3CGCSF1R
SCHEMBL2845178 0.78 CSF1R (0.49) PI4KAPI4KBPIP5K1CPIK3CGCSF1R
SCHEMBL2852428 0.76 NPC1 (0.44) PI4KAPI4KBPIP5K1CPIK3CGCSF1R
SCHEMBL2852429 0.76 NPC1 (0.44) PI4KAPI4KBPIP5K1CPIK3CGCSF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2152700-B1 CSF-1R INHIBITORS, COMPOSITIONS, AND METHODS OF USE NOVARTIS AG (CH) 2013-12-11 EP claimed
US-8293769-B2 CSF-1R inhibitors, compositions, and methods of use NOVARTIS AG (CH) 2012-10-23 US claimed
US-20100130490-A1 CSF-1R INHIBITORS,COMPOSITIONS, AND METHODS OF USE NOVARTIS AG (CH) 2010-05-27 US claimed
EP-2152700-B1 CSF-1R INHIBITORS, COMPOSITIONS, AND METHODS OF USE NOVARTIS AG (CH) 2013-12-11 EP disclosed
US-8293769-B2 CSF-1R inhibitors, compositions, and methods of use NOVARTIS AG (CH) 2012-10-23 US disclosed
US-20100130490-A1 CSF-1R INHIBITORS,COMPOSITIONS, AND METHODS OF USE NOVARTIS AG (CH) 2010-05-27 US disclosed
EP-2152700-A1 CSF-1R INHIBITORS, COMPOSITIONS, AND METHODS OF USE Novartis Ag (CH) 2010-02-17 EP disclosed
WO-2008144062-A1 CSF-1R INHIBITORS, COMPOSITIONS, AND METHODS OF USE NOVARTIS AG (CH) 2008-11-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100130490-A1 CSF-1R INHIBITORS,COMPOSITIONS, AND METHODS OF USE CSF1R, CSF3R, FLT3 PI4KA 2704/4885PI4KB 2144/4885PIP5K1C 4295/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.